• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2023

View Archived Issues
Illustration of leg anatomy with target around knee

Partially blocking inflammatory receptor could lead to treatment for osteoarthritis

Partially blocking a receptor that helps regulate the activity of the inflammatory cytokine molecule interleukin-6 (IL-6) seems to promote tissue regeneration and block degeneration in a model of osteoarthritis. As reported in the March 22, 2023, issue of Science Translational Medicine, the receptor, called glycoprotein 130 (gp130), regulates both positive and negative inflammatory responses that can help regenerate tissue, but also cause degeneration. Read More

RHOJ protein helps skin cancer resist chemotherapy

RHOJ, a small GTPase, could hold the key to the survival of tumor cells during cancer treatments. When epithelial cells transformed into mesenchymal cells, the Rho-related GTP-binding protein RhoJ regulated their resistance to chemotherapy. The scientists observed this mechanism in mouse models of skin squamous cell carcinoma, but their results could go beyond just one type of cancer. When the team started its experiments, which were published March 23, 2023, in Nature, “I had never heard about RHOJ before,” the lead author Cédric Blanpain told BioWorld. Blanpain is the director of the Laboratory of Stem Cells and Cancer at the Université Libre de Bruxelles (ULB). Read More
Degradation of motor neurons

A novel CAPN2-targeting ASO, AMX-0114, rescues neurite degeneration in vitro

Calcium-dependent protease calpain-2 (CAPN2) has been previously proposed as a critical effector of axonal degeneration, which is a key early... Read More
Tumor microenvironment

Lanzhou University researchers identify novel anti-TrxR curcumin analogue

Uncontrolled growth, invasion and angiogenesis are malignant characteristics of cancer cells mediated by increased reactive oxygen species... Read More

Stealth Biotherapeutics presents preclinical data for SBT-272 in neurodegeneration

SBT-272 (Stealth Biotherapeutics Inc.) is a small molecule for treating mitochondrial dysfunction in neurodegenerative disorders, and the function... Read More
DNA, drug development concept art.

Moderna and Generation Bio collaborate to develop nonviral genetic medicines

Moderna Inc. and Generation Bio Co. have entered into a strategic collaboration to combine Moderna’s biological and technical expertise... Read More

Targeting GPR10 as therapeutic strategy for obesity

It has been previously demonstrated that disruption of brain-expressed G protein-coupled receptor-10 (GPR10) causes obesity in animals... Read More

Kunshan Xinyunda Biotechnology patents new antibody-drug conjugates for cancer

Kunshan Xinyunda Biotechnology Co. Ltd. has disclosed antibody-drug conjugates comprising an antibody linked to cytotoxic drug through a linker... Read More
AI-digital-health.png

Evaxion’s AI technology leads to identification of new viral targets for cancer immunotherapy

Evaxion Biotech A/S has developed a new proprietary artificial intelligence (AI) platform technology, Observ, to identify a new source of targets for personalized cancer therapy, potentially enabling treatment for patients with cold tumors, normally unresponsive to immunotherapy. Read More

Japanese researchers divulge new plasmalogen derivatives

Institute of Rheological Function of Food Co. Ltd. and Kyushu University have synthesized plasmalogen derivatives reported to be useful for the treatment of dementia, Rett syndrome, Parkinson’s disease, depression and schizophrenia. Read More

S100A9 identified as a therapeutic target in paclitaxel-induced peripheral neuropathy

When tissue injury occurs, stressed cells release a bunch of intracellular molecules called damage-associated molecular pattern (DAMP) proteins. S100 calcium binding protein A9 (S100A9) is a DAMP usually found in macrophages and is involved in multiple inflammatory responses, such as activation of Toll-like receptor 4 (TLR4). Read More
Muscular dystrophy

EPI-321 gene therapy leads phenotypic rescue in humanized murine model of FSHD

Facioscapulohumeral muscular dystrophy (FSHD) is a skeletal muscular dystrophy characterized by DNA hypomethylation of D4Z4 repeat units of a macrosatellite array found at the distal end of chromosome region 4q35, which causes a myotoxic expression of DUX4. Researchers from Epic-Bio presented the discovery of EPI-321, a novel gene therapy candidate for the treatment of FSHD. Read More

Roche describes new GTPase KRAS mutant inhibitors for cancer

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified macrocyclic compounds acting as GTPase KRAS (G12C) mutant inhibitors reported to be useful for the treatment of cancer. Read More

Nanjing Zhihe Pharmaceutical presents new cytidine derivatives for viral infections

Nanjing Zhihe Pharmaceutical Technology Co. Ltd. has divulged cytidine derivatives reported to be useful for the treatment of viral infections. Read More
Obesity, fat cell research concept image

SAPS3: a negative regulator of AMPK controlling metabolic homeostasis in mice under high-fat diet

The AMP-activated protein kinase (AMPK) is a sensor of metabolic stress and a key mediator in preserving metabolic homeostasis both at the cellular and organism levels. AMPK activation is considered a targetable mechanism for diseases associated with metabolic perturbations, such as diabetes, obesity, fatty liver disease and cancer, among others. However, the regulators of AMPK that antagonize AMPK activators remain unknown, although they are critical to efficiently target AMPK activation for therapeutic purposes. Read More

Northwest Agriculture & Forestry University discovers new NADH-ubiquinone oxidoreductase inhibitors

Northwest Agriculture & Forestry University has described thiazolecarboxamidine compounds acting as NADH-ubiquinone oxidoreductase (complex I) inhibitors reported to be useful for the treatment of cancer. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 16, 2025.
  • Art concept for bladder

    Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

    BioWorld
    During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe